Olga M. Filippova
Olga M. Filippova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Sergey Yu. Petrov
Helmholtz National Medical Research Center of Eye Disease
12 shared publications - Anastasiia N. Zhuravleva
Helmholtz National Medical Research Center of Eye Diseases
5 shared publications - Oksana I. Markelova
Helmholtz National Medical Research Center of Eye Diseases
5 shared publications O. M. Kalinina
Helmholtz National Medical Research Center of Eye Diseases
4 shared publications- L. V. Yakubova
Helmholtz National Medical Research Center of Eye Diseases
3 shared publications - S. M. Kosakyan
Helmholtz National Medical Research Center of Eye Diseases
3 shared publications
Latest Publications
- 5 April 2026
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 19 (1)
Brinzolamide/brimonidine fixed combination for open-angle glaucoma and ocular hypertension treatment: hypotensive efficacy and tolerability
The literature review analyzes the data of 12-year clinical use of a fixed combination of 1% brinzolamide and 0.2 % brimonidine (BBFC) in the treatment of glaucoma and ocular hypertension. This drug is an alternative for patients with systemic contraindications in the form of broncho-obstructive syndrome and cardiovascular pathology. The monotherapy BBFC hypotensive effect is 30 % of the IOP initial level and corresponds to that of brinzolamide/brimonidine non-fixed combination. Switching patients with glaucoma and ocular hypertension from monotherapy with brinzolamide or brimonidine to BBFC is accompanied by an additional hypotensive effect at the of 13% of the initial IOP. BBFC has a good additional hypotensive effect in combination with drugs of other pharmaceutical groups, and also effectively relieves the hypertension after laser capsulotomy, intravitreal anti-VEGF injections and phacoemulsification. The most common BBFC ophthalmological adverse effects are conjunctival hyperemia, conjunctivitis, allergic reactions and eye discomfort with a frequency of about 10–20 %.
- 5 April 2026
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 19 (1)
Brinzolamide/brimonidine fixed combination for open-angle glaucoma and ocular hypertension treatment: hypotensive efficacy and tolerability
The literature review analyzes the data of 12-year clinical use of a fixed combination of 1% brinzolamide and 0.2 % brimonidine (BBFC) in the treatment of glaucoma and ocular hypertension. This drug is an alternative for patients with systemic contraindications in the form of broncho-obstructive syndrome and cardiovascular pathology. The monotherapy BBFC hypotensive effect is 30 % of the IOP initial level and corresponds to that of brinzolamide/brimonidine non-fixed combination. Switching patients with glaucoma and ocular hypertension from monotherapy with brinzolamide or brimonidine to BBFC is accompanied by an additional hypotensive effect at the of 13% of the initial IOP. BBFC has a good additional hypotensive effect in combination with drugs of other pharmaceutical groups, and also effectively relieves the hypertension after laser capsulotomy, intravitreal anti-VEGF injections and phacoemulsification. The most common BBFC ophthalmological adverse effects are conjunctival hyperemia, conjunctivitis, allergic reactions and eye discomfort with a frequency of about 10–20 %.
- Open Access
- 9 January 2026
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 18 (4) , 34-38
Early results of Preserflo MicroShunt implantation in primary open-angle glaucoma
Purpose: to evaluate the efficacy and safety of Preserflo MicroShunt implantation in patients with primary open-angle glaucoma (POAG) as the first and second glaucoma surgery in the early postoperative period. Material and methods. Single-center prospective non-randomized study of Preserflo MicroShunt implantation in 12 patients (12 eyes) aged 60,4 ± 17,8 with moderate and advanced POAG with an average IOP of 30.3 ± 9.1 mm Hg. IOP was determined at 1, 3, 7 days, 2 weeks, 1 and 3 months after surgery. Results. The IOP level was 10.2 ± 5.0, 9.4 ± 4.4, 11.3 ± 4.5, 10.8 ± 4.2, 12.7 ± 5.6 and 13.0 ± 6.1 mm Hg, respectively. Baseline average visual acuity was 0.5 ± 0.3, unchanged either on day 7 or by 3 month. Hypotony £ 6 mmHg was in 4 cases, with a flat anterior chamber and choroidal effusion without Seidel positive leakage in 2 cases, without anterior chamber reformation. In 5 cases, IOP increase required bleb needling filtration, and in 2 cases — the medication therapy restart. Conclusion. Preserflo MicroShunt implantation in patients with POAG is an effective and safe procedure for up to 3 months after surgery.
- 9 January 2026
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 18 (4) , 34-38
Open AccessEarly results of Preserflo MicroShunt implantation in primary open-angle glaucoma
Purpose: to evaluate the efficacy and safety of Preserflo MicroShunt implantation in patients with primary open-angle glaucoma (POAG) as the first and second glaucoma surgery in the early postoperative period. Material and methods. Single-center prospective non-randomized study of Preserflo MicroShunt implantation in 12 patients (12 eyes) aged 60,4 ± 17,8 with moderate and advanced POAG with an average IOP of 30.3 ± 9.1 mm Hg. IOP was determined at 1, 3, 7 days, 2 weeks, 1 and 3 months after surgery. Results. The IOP level was 10.2 ± 5.0, 9.4 ± 4.4, 11.3 ± 4.5, 10.8 ± 4.2, 12.7 ± 5.6 and 13.0 ± 6.1 mm Hg, respectively. Baseline average visual acuity was 0.5 ± 0.3, unchanged either on day 7 or by 3 month. Hypotony £ 6 mmHg was in 4 cases, with a flat anterior chamber and choroidal effusion without Seidel positive leakage in 2 cases, without anterior chamber reformation. In 5 cases, IOP increase required bleb needling filtration, and in 2 cases — the medication therapy restart. Conclusion. Preserflo MicroShunt implantation in patients with POAG is an effective and safe procedure for up to 3 months after surgery.
- Open Access
- 17 September 2025
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 18 (3) , 152-157
Wound healing in glaucoma surgery. Part 4. Postoperative methods
Glaucoma surgery is currently the most effective method of intraocular pressure reducing. However, the wound healing surgical area processes prevent the intraocular fluid outflow, that reduce the long-term effectiveness of the surgery. A highly effective method of preventing scarring is the use of cytostatics, however, the lack of official indications and significant side effects limit it’s use. Currently, there are more than three dozen different methods of intraand postoperative antiscar therapy, including cytostatic, anti-inflammatory, anti-angiogenic and anti-neoplastic drugs, as well as the use of β-radiation and cross-linking.
- 17 September 2025
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 18 (3) , 152-157
Open AccessWound healing in glaucoma surgery. Part 4. Postoperative methods
Glaucoma surgery is currently the most effective method of intraocular pressure reducing. However, the wound healing surgical area processes prevent the intraocular fluid outflow, that reduce the long-term effectiveness of the surgery. A highly effective method of preventing scarring is the use of cytostatics, however, the lack of official indications and significant side effects limit it’s use. Currently, there are more than three dozen different methods of intraand postoperative antiscar therapy, including cytostatic, anti-inflammatory, anti-angiogenic and anti-neoplastic drugs, as well as the use of β-radiation and cross-linking.
- Open Access
- 14 June 2025
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 18 (2) , 153-159
Wound healing in glaucoma surgery. Part 3. Methods of preoperative prevention
Study of factors preventing excessive scarring in antiglaucoma surgery creates a foundation for developing methods of influencing these processes in the postoperative period in order to increase the effectiveness of the intervention. Analysis of the literature showed that a systematic approach to preparing for successful surgical treatment of glaucoma should include a rational choice of previous hypotensive therapy with preservative-free drugs, prevention of damage to the ocular surface using tear substitute and immunosuppressive therapy, as well as preoperative anti-inflammatory prophylaxis with steroid and non-steroid agents with proven ophthalmic hypertension safety.
- 14 June 2025
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 18 (2) , 153-159
Open AccessWound healing in glaucoma surgery. Part 3. Methods of preoperative prevention
Study of factors preventing excessive scarring in antiglaucoma surgery creates a foundation for developing methods of influencing these processes in the postoperative period in order to increase the effectiveness of the intervention. Analysis of the literature showed that a systematic approach to preparing for successful surgical treatment of glaucoma should include a rational choice of previous hypotensive therapy with preservative-free drugs, prevention of damage to the ocular surface using tear substitute and immunosuppressive therapy, as well as preoperative anti-inflammatory prophylaxis with steroid and non-steroid agents with proven ophthalmic hypertension safety.
- Open Access
- 1 October 2024
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 17 (3) , 7-12
Glaucoma epidemiology in the Russian Federation
Glaucoma is worldwide the most common cause of irreversible blindness. Its prevalence in the population older than 40 years is about 3.5 %, and correlates with age. The most common type is primary open-angle glaucoma (POAG). The global prevalence of POAG is expected to grow from 76.0 million in 2020 to 111.8 million by 2040. In 2022, a total of 1,250,558 patients with glaucoma were registered in the Russian Federation, of which 110,680 had newly diagnosed glaucoma. The overall glaucoma incidence rate in Russia shows a steady growth: in 2022, it increased by 30 % as compared to 2013. In order to meet the challenge, medical care of glaucomatous patients is on the rise: the contingent receiving dispensary observation increased by 6.8 % over the last 10 years, whilst surgical treatment involved 28.1 % more patients.
- 1 October 2024
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 17 (3) , 7-12
Open AccessGlaucoma epidemiology in the Russian Federation
Glaucoma is worldwide the most common cause of irreversible blindness. Its prevalence in the population older than 40 years is about 3.5 %, and correlates with age. The most common type is primary open-angle glaucoma (POAG). The global prevalence of POAG is expected to grow from 76.0 million in 2020 to 111.8 million by 2040. In 2022, a total of 1,250,558 patients with glaucoma were registered in the Russian Federation, of which 110,680 had newly diagnosed glaucoma. The overall glaucoma incidence rate in Russia shows a steady growth: in 2022, it increased by 30 % as compared to 2013. In order to meet the challenge, medical care of glaucomatous patients is on the rise: the contingent receiving dispensary observation increased by 6.8 % over the last 10 years, whilst surgical treatment involved 28.1 % more patients.
- 2 July 2024
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 17 (2)
Current trends and prospects of the local antihypertensive drugs development for the glaucoma treatment
Glaucoma is one of the world’s primary causes of blindness. Russia is following the global increasing trends of glaucoma and its leading position among ophthalmic pathologies that cause irreversible loss of vision. Elevated intraocular pressure (IOP) is the only modifiable risk factor of glaucoma, so treatment strategies specifically focus on reducing IOP by suppressing the production of intraocular fluid and boosting its outflow. The current review presents new medications aimed at glaucoma and high IOP control that have recently appeared at the international market as well as the drugs under the different stages of development, from experimental to clinical studies. These include both the developments of agents belonging to the existing classes and of entirely new drugs intended to control IOP. In an attempt to reduce the side effects of locally administered drugs and prolong their action, in parallel with the development of new drugs, there is also evidence of alternative methods of drug delivery: intraocular implants, injectable forms and obturators, combinations of polymers and colloidal systems.
- 2 July 2024
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 17 (2)
Current trends and prospects of the local antihypertensive drugs development for the glaucoma treatment
Glaucoma is one of the world’s primary causes of blindness. Russia is following the global increasing trends of glaucoma and its leading position among ophthalmic pathologies that cause irreversible loss of vision. Elevated intraocular pressure (IOP) is the only modifiable risk factor of glaucoma, so treatment strategies specifically focus on reducing IOP by suppressing the production of intraocular fluid and boosting its outflow. The current review presents new medications aimed at glaucoma and high IOP control that have recently appeared at the international market as well as the drugs under the different stages of development, from experimental to clinical studies. These include both the developments of agents belonging to the existing classes and of entirely new drugs intended to control IOP. In an attempt to reduce the side effects of locally administered drugs and prolong their action, in parallel with the development of new drugs, there is also evidence of alternative methods of drug delivery: intraocular implants, injectable forms and obturators, combinations of polymers and colloidal systems.
- Open Access
- 9 March 2024
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 17 (1) , 29-38
The influence of post-COVID-19 syndrome on microcirculation of the optic nerve head among patients with primary open-angle glaucoma
BACKGROUND: Glaucoma is one of the leading causes of blindness in the world. This is a multifactorial ophthalmopathology, which also results from impaired microcirculation in the optic nerve. One of the diseases affecting ocular blood flow is acute coronavirus infection (COVID-19). AIM: The aim of this study is the assessment of blood flow parameters of the optic nerve head in patients with primary open-angle glaucoma (POAG) against the background of post-COVID-19 syndrome using laser speckle flowgraphy. MATERIALS AND METHODS: The study included 40 patients with advanced stage primary open-angle glaucoma who had COVID-19 within the previous 3 months. Patients were divided into 2 subgroups depending on the severity of the disease. The comparison group consisted of 20 individuals with an advanced stage of primary open-angle glaucoma who did not have COVID-19. All subjects were over 60 years old and had normal blood pressure parameters. Optic nerve head blood flow was measured using the LSFG-NAVI device (Japan) and assessed by LSFG Analyzer software. MBR parameters (MA, MV and MT), as well as pulse wave indicators (Skew, BOS, BOT, RR, FR, FAI, ATI and RI) were analyzed. RESULTS: The most significant decrease was found for the MV and MT parameters, reflecting the blood flow in large vessels and the microvasculature of the optic disc. MV decrease by 20%, MT — by 23%, MA — by 16% were noted, as well as pulse wave parameter changes, in patients with an advanced stage of primary open-angle glaucoma, post-COVID syndrome after moderate COVID-19 compared with patients with an advanced stage of primary open-angle glaucoma who did not have COVID-19 (p ≤ 0.05). CONCLUSIONS: Laser speckle flowgraphy allows rapid and effective assessment of ocular blood flow. Parameters estimated at the examination may be considered as new biomarkers for the detection and evaluation of vascular diseases.
- 9 March 2024
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 17 (1) , 29-38
Open AccessThe influence of post-COVID-19 syndrome on microcirculation of the optic nerve head among patients with primary open-angle glaucoma
BACKGROUND: Glaucoma is one of the leading causes of blindness in the world. This is a multifactorial ophthalmopathology, which also results from impaired microcirculation in the optic nerve. One of the diseases affecting ocular blood flow is acute coronavirus infection (COVID-19). AIM: The aim of this study is the assessment of blood flow parameters of the optic nerve head in patients with primary open-angle glaucoma (POAG) against the background of post-COVID-19 syndrome using laser speckle flowgraphy. MATERIALS AND METHODS: The study included 40 patients with advanced stage primary open-angle glaucoma who had COVID-19 within the previous 3 months. Patients were divided into 2 subgroups depending on the severity of the disease. The comparison group consisted of 20 individuals with an advanced stage of primary open-angle glaucoma who did not have COVID-19. All subjects were over 60 years old and had normal blood pressure parameters. Optic nerve head blood flow was measured using the LSFG-NAVI device (Japan) and assessed by LSFG Analyzer software. MBR parameters (MA, MV and MT), as well as pulse wave indicators (Skew, BOS, BOT, RR, FR, FAI, ATI and RI) were analyzed. RESULTS: The most significant decrease was found for the MV and MT parameters, reflecting the blood flow in large vessels and the microvasculature of the optic disc. MV decrease by 20%, MT — by 23%, MA — by 16% were noted, as well as pulse wave parameter changes, in patients with an advanced stage of primary open-angle glaucoma, post-COVID syndrome after moderate COVID-19 compared with patients with an advanced stage of primary open-angle glaucoma who did not have COVID-19 (p ≤ 0.05). CONCLUSIONS: Laser speckle flowgraphy allows rapid and effective assessment of ocular blood flow. Parameters estimated at the examination may be considered as new biomarkers for the detection and evaluation of vascular diseases.
- Open Access
- 29 December 2023
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 16 (4) , 69-80
Efficacy and safety of the initial hypotensive treatment with an optimized latanoprost composition
Purpose: a comparative study of the efficacy and safety of Latanoprost-Optic, a new composition of excipients and the original latanoprost, in the initial therapy of primary open-angle glaucoma (POAG)Material and methods. We performed a prospective, randomized, comparative study of 60 previously untreated patients (71 eyes) with early and advanced POAG stages. During the screening visit, patients were randomly divided into the main (Latanoprost-Optic) and the control (original latanoprost) groups. The target points included intraocular pressure (IOP), visual acuity, MD and PSD perimetry indices, RNFL thickness, MRW, NFL, GCL, IPL, tear film break time, OSDI, and adverse events. The observation period was 12 weeks. IOP was measured 4 and 12 weeks from observation start.Results. The average decrease in IOP in the study group by the end of the observation was 32% and did not show any statistically significant differences from the original drug at any control point. A positive unreliable dynamic of the values of most functional parameters was noted, which may indicate the presence of an indirect neuroprotective effect. In the study group, there was a positive trend in tear film rupture time and OSDI. According to corneal confocal microscopy, no negative changes in dynamics were noted, in contrast to the control group. Reversible discomfort and mild redness of the bulbar conjunctiva were recorded in both groups. No serious or systemic adverse events were noted.Conclusion. Latanoprost-Optic has a hypotensive efficacy, comparable to the original latanoprost, and a high favorable safety profile.
- 29 December 2023
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 16 (4) , 69-80
Open AccessEfficacy and safety of the initial hypotensive treatment with an optimized latanoprost composition
Purpose: a comparative study of the efficacy and safety of Latanoprost-Optic, a new composition of excipients and the original latanoprost, in the initial therapy of primary open-angle glaucoma (POAG)Material and methods. We performed a prospective, randomized, comparative study of 60 previously untreated patients (71 eyes) with early and advanced POAG stages. During the screening visit, patients were randomly divided into the main (Latanoprost-Optic) and the control (original latanoprost) groups. The target points included intraocular pressure (IOP), visual acuity, MD and PSD perimetry indices, RNFL thickness, MRW, NFL, GCL, IPL, tear film break time, OSDI, and adverse events. The observation period was 12 weeks. IOP was measured 4 and 12 weeks from observation start.Results. The average decrease in IOP in the study group by the end of the observation was 32% and did not show any statistically significant differences from the original drug at any control point. A positive unreliable dynamic of the values of most functional parameters was noted, which may indicate the presence of an indirect neuroprotective effect. In the study group, there was a positive trend in tear film rupture time and OSDI. According to corneal confocal microscopy, no negative changes in dynamics were noted, in contrast to the control group. Reversible discomfort and mild redness of the bulbar conjunctiva were recorded in both groups. No serious or systemic adverse events were noted.Conclusion. Latanoprost-Optic has a hypotensive efficacy, comparable to the original latanoprost, and a high favorable safety profile.
- Open Access
- 10 October 2023
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 16 (3) , 60-68
Efficiency and safety of the fixed latanoprost/ dorzolamide combination in open-angle glaucoma hypotensive treatment
Purpose: to determine the efficacy and safety of fixed latanoprost/dorzolamide combination Dorzoprost in hypotensive treatment of primary open-angle glaucoma (POAG) patients previously treated with latanoprost.Material and methods. An observational study included 30 patients (37 eyes) with moderate and advanced POAG who had uncompensated elevated IOP receiving latanoprost monotherapy. During the screening visit, latanoprost was switched to Dorzoprost instilled once in the evening. The targets were IOP, visual acuity, MD and PSD perimetry indices, retinal nerve fiber layer thickness, minimum width of the neuroretinal rim, macula retinal nerve fiber layer thickness, and adverse events. The observation period lasted 12 weeks. IOP was measured at weeks 4 and 12.Results. After 4 weeks, a statistically significant decrease in IOP was noted, which remained stable at 12 weeks. The average additional IOP decrease of those treated with Dorzoprost was 17%. Statistically insignificant positive changes were registered in visual acuity, static perimetry and optical coherence tomography. By the end of the observation period, 6 cases revealed a decrease in the degree of conjunctival hyperemia, while all dry eye syndrome cases (5 patients) showed a decrease in the severity of the signs of the syndrome.Conclusion. Dorzoprost has a significant additive hypotensive effect and a favorable safety profile.
- 10 October 2023
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 16 (3) , 60-68
Open AccessEfficiency and safety of the fixed latanoprost/ dorzolamide combination in open-angle glaucoma hypotensive treatment
Purpose: to determine the efficacy and safety of fixed latanoprost/dorzolamide combination Dorzoprost in hypotensive treatment of primary open-angle glaucoma (POAG) patients previously treated with latanoprost.Material and methods. An observational study included 30 patients (37 eyes) with moderate and advanced POAG who had uncompensated elevated IOP receiving latanoprost monotherapy. During the screening visit, latanoprost was switched to Dorzoprost instilled once in the evening. The targets were IOP, visual acuity, MD and PSD perimetry indices, retinal nerve fiber layer thickness, minimum width of the neuroretinal rim, macula retinal nerve fiber layer thickness, and adverse events. The observation period lasted 12 weeks. IOP was measured at weeks 4 and 12.Results. After 4 weeks, a statistically significant decrease in IOP was noted, which remained stable at 12 weeks. The average additional IOP decrease of those treated with Dorzoprost was 17%. Statistically insignificant positive changes were registered in visual acuity, static perimetry and optical coherence tomography. By the end of the observation period, 6 cases revealed a decrease in the degree of conjunctival hyperemia, while all dry eye syndrome cases (5 patients) showed a decrease in the severity of the signs of the syndrome.Conclusion. Dorzoprost has a significant additive hypotensive effect and a favorable safety profile.
- Open Access
- 14 July 2023
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 16 (2) , 7-15
Transpalpebral tonometry as a priority method for intraocular pressure monitoring in corneal pathology
BACKGROUND: Measurement of intraocular pressure in the presence of combined ophthalmic condition could determine further therapy and prognosis. However, tonometry in corneal diseases could lead to unreliable results. The search for methods for intraocular pressure measurement in these settings is a critical task intended to expand diagnostic capabilities. AIM: Evaluation of the transpalpebral tonometry diagnostic value for intraocular pressure monitoring in patients with corneal conditions of various origin. MATERIALS AND METHODS: Measurements of intraocular pressure were carried out in 39 patients with glaucoma and/or cataract (mean age 62.34 9.1), with corneal changes due to various ophthalmic conditions: post-traumatic scars; keratotomy scars as a result of refractive surgery; corneal defects due to ulcerative process of various etiology; corneal erosions; bullous keratopathy; deformities and leukomas after surgical treatment of pterygium or exposure to an infectious agent. Intraocular pressure measurement was carried out using several methods: palpation, using rebound and transpalpebral tonometry, in some cases tonometry was performed according to Maklakov method. RESULTS: The averaged data were comparable: palpation; rebound tonometry 23.34 4.7 mm Hg; transpalpebral tonometry 24.27 4.7 mm Hg; and Maklakov tonometry 23.16 5.4 mm Hg. The accuracy and reproducibility of measurement results increased significantly with the improvement of skills in using tonometers. CONCLUSIONS: Transpalpebral tonometry using TVGD-02 tonometer makes it possible to adequately assess intraocular pressure in patients with corneal pathology. The absence of contact during the implementation of technique makes it possible to recognize it as a priority when measuring intraocular pressure in certain categories of patients.
- 14 July 2023
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 16 (2) , 7-15
Open AccessTranspalpebral tonometry as a priority method for intraocular pressure monitoring in corneal pathology
BACKGROUND: Measurement of intraocular pressure in the presence of combined ophthalmic condition could determine further therapy and prognosis. However, tonometry in corneal diseases could lead to unreliable results. The search for methods for intraocular pressure measurement in these settings is a critical task intended to expand diagnostic capabilities. AIM: Evaluation of the transpalpebral tonometry diagnostic value for intraocular pressure monitoring in patients with corneal conditions of various origin. MATERIALS AND METHODS: Measurements of intraocular pressure were carried out in 39 patients with glaucoma and/or cataract (mean age 62.34 9.1), with corneal changes due to various ophthalmic conditions: post-traumatic scars; keratotomy scars as a result of refractive surgery; corneal defects due to ulcerative process of various etiology; corneal erosions; bullous keratopathy; deformities and leukomas after surgical treatment of pterygium or exposure to an infectious agent. Intraocular pressure measurement was carried out using several methods: palpation, using rebound and transpalpebral tonometry, in some cases tonometry was performed according to Maklakov method. RESULTS: The averaged data were comparable: palpation; rebound tonometry 23.34 4.7 mm Hg; transpalpebral tonometry 24.27 4.7 mm Hg; and Maklakov tonometry 23.16 5.4 mm Hg. The accuracy and reproducibility of measurement results increased significantly with the improvement of skills in using tonometers. CONCLUSIONS: Transpalpebral tonometry using TVGD-02 tonometer makes it possible to adequately assess intraocular pressure in patients with corneal pathology. The absence of contact during the implementation of technique makes it possible to recognize it as a priority when measuring intraocular pressure in certain categories of patients.